The Hospitalization-Related Costs of Adverse Events for Novel Androgen Receptor Inhibitors in Non-Metastatic Castration-Resistant Prostate Cancer: An Indirect Comparison

INTRODUCTION: Three novel androgen receptor inhibitors are approved in the USA for the treatment of non-metastatic castration-resistant prostate cancer (nmCRPC): apalutamide, enzalutamide, and darolutamide. All three therapies have demonstrated prolonged metastasis-free survival in their respective...

Descripción completa

Detalles Bibliográficos
Autores principales: Shore, Neal, Jiang, Shan, Garcia-Horton, Viviana, Terasawa, Emi, Steffen, David, Chin, Andi, Ayyagari, Rajeev, Partridge, Jamie, Waldeck, A. Reginald
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Healthcare 2022
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9525430/
https://www.ncbi.nlm.nih.gov/pubmed/36028656
http://dx.doi.org/10.1007/s12325-022-02245-8

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9525430/
https://www.ncbi.nlm.nih.gov/pubmed/36028656
http://dx.doi.org/10.1007/s12325-022-02245-8

Ejemplares similares